Yangtze River Pharmaceutical Group Co.

Taizhou, China

Yangtze River Pharmaceutical Group Co.

Taizhou, China
SEARCH FILTERS
Time filter
Source Type

Erectile Dysfunction Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Erectile Dysfunction Drugs (Male Health) complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer. Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1141789. The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Companies discussed in this report include  Apricus Biosciences Inc , Astellas Pharma Inc , Biolab Farmaceutica Ltda , Biopharm GmbH , Can-Fite BioPharma Ltd , Fabre-Kramer Pharmaceuticals Inc , Futura Medical Plc , Hanmi Pharmaceuticals Co Ltd , Humanetics Corp , IntelGenx Corp , Ion Channel Innovations LLC , iX Biopharma Ltd , Mezzion Pharma Co Ltd, Mitsubishi Tanabe Pharma Corp , Monosol Rx LLC , N4 Pharma Plc , NAL Pharmaceuticals Ltd , Nanoform Cardiovascular Therapeutics Ltd , Palatin Technologies Inc , Pharmicell Co Ltd , SK Chemicals Co Ltd , Suda Ltd , XuanZhu Pharma Co Ltd , Yangtze River Pharmaceutical Group , Yungjin Pharm Co Ltd. Drug Profile Discussed In Report: alprostadil , AP-185 , avanafil , BIO-300 , BL-214 , Cellgram-ED , CF-602 , fadanafil , FKK-01PD , HCP-1302 , IPED-2015 , MED-2002 , MED-2005 , mirabegron ER , moxisylyte , Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health , pVAX-hSlo , Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease , sildenafil , sildenafil citrate , sildenafil citrate , sildenafil citrate , sildenafil citrate , Small Molecule to Inhibit PDE5 for Erectile Dysfunction , SUD-003 , Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction , T-6932 , tadalafil , tadalafil , tadalafil , tadalafil , tadalafil , TF-0092 , TPN-729 , TR-399 , udenafil , YBH-1603 , Yonkenafil. Erectile Dysfunction - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Erectile Dysfunction in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Erectile Dysfunction prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Erectile Dysfunction. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by team of industry experts. RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-08-09

Provided are azabicyclo derivatives, a process for preparation thereof and medical use thereof. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof, a process for preparation thereof, and application thereof in preparing EGFR (Epidermal Growth Factor Receptor) inhibitors. Definition of each group in the formula can be found in the description for details.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-01-11

The present invention discloses a series of piperidine derivatives as orexin receptor antagonists and compositions thereof, and relates to the application thereof in preparing medications for the treatment of insomnia, chronic obstructive pulmonary disease, obstructive sleep apnea, hypersomnia, anxiety, obsessive-compulsive disorder, panic attack, nicotine addiction, or binge eating disorder.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-03-22

The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-01-04

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.


Erectile Dysfunction Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Erectile Dysfunction Drugs (Male Health) complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer. Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1141789. The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 4, 5, 3, 2, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Companies discussed in this report include  Apricus Biosciences Inc , Astellas Pharma Inc , Biolab Farmaceutica Ltda , Biopharm GmbH , Can-Fite BioPharma Ltd , Fabre-Kramer Pharmaceuticals Inc , Futura Medical Plc , Hanmi Pharmaceuticals Co Ltd , Humanetics Corp , IntelGenx Corp , Ion Channel Innovations LLC , iX Biopharma Ltd , Mezzion Pharma Co Ltd, Mitsubishi Tanabe Pharma Corp , Monosol Rx LLC , N4 Pharma Plc , NAL Pharmaceuticals Ltd , Nanoform Cardiovascular Therapeutics Ltd , Palatin Technologies Inc , Pharmicell Co Ltd , SK Chemicals Co Ltd , Suda Ltd , XuanZhu Pharma Co Ltd , Yangtze River Pharmaceutical Group , Yungjin Pharm Co Ltd. Drug Profile Discussed In Report: alprostadil , AP-185 , avanafil , BIO-300 , BL-214 , Cellgram-ED , CF-602 , fadanafil , FKK-01PD , HCP-1302 , IPED-2015 , MED-2002 , MED-2005 , mirabegron ER , moxisylyte , Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health , pVAX-hSlo , Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease , sildenafil , sildenafil citrate , sildenafil citrate , sildenafil citrate , sildenafil citrate , Small Molecule to Inhibit PDE5 for Erectile Dysfunction , SUD-003 , Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction , T-6932 , tadalafil , tadalafil , tadalafil , tadalafil , tadalafil , TF-0092 , TPN-729 , TR-399 , udenafil , YBH-1603 , Yonkenafil. Erectile Dysfunction - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Erectile Dysfunction in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Erectile Dysfunction prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Erectile Dysfunction. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by team of industry experts. RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2017-05-31

The present invention relates to a 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (I), see the description for details.


Patent
Shanghai Haiyan Pharmaceutical Technology Co. and Yangtze River Pharmaceutical Group Co. | Date: 2015-04-13

The present invention relates to 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, a preparation method therefor and a medicinal use thereof. Specifically, disclosed are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, preparation method therefor and application thereof. Definition of each group in the formula can be found in the specification for details.


The present application discloses an A-type polymorphic substance of yonkenafil hydrochloride and a preparation method, a composition and use thereof. The powder diffraction pattern of the A-type polymorphic substance of yonkenafil hydrochloride comprises diffraction peaks at three or more 2 values selected from: 8.4 0.2, 11.3 0.2, 13.9 0.2, 14.2 0.2, 14.7 0.2, 16.8 0.2, 17.1 0.2, 19.7 0.2, 21.0 0.2, 21.7 0.2, 22.4 0.2, 23.3 0.2, 23.8 0.2, 26.8 0.2, 27.5 0.2, 28.0 0.2.


Patent
SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY Co. and Yangtze River Pharmaceutical Group Co. | Date: 2015-02-13

The present invention provides a class of 2,4-substituted phenylene-1,5-diamine derivatives, having an inhibiting effect on EGFR tyrosine kinases, and pharmaceutically acceptable salt, stereoisomer, solvate or prodrug of said derivatives. See the description for the definition of each group in the formula. In addition, the present invention also discloses pharmaceutical compositions, pharmaceutically acceptable compositions and applications thereof.

Loading Yangtze River Pharmaceutical Group Co. collaborators
Loading Yangtze River Pharmaceutical Group Co. collaborators